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Abstract
Effects of Dietary Fats on Mechanisms of Adipose Expansion and Function
Allison Marie Wing
2021
Obesity, defined as the excessive accumulation of white adipose tissue
(WAT), is a global pandemic and increases risk of many other pathologies.
However, in vivo molecular mechanisms of adipocyte formation, or adipogenesis,
during obesity and high-fat diet (HFD) consumption are still being understood.
WAT can expand either through the proliferation of adipocyte precursors (APs)
and their differentiation to form new adipocytes (adipogenesis) or through the
increased size of adipocytes (hypertrophy). To study how dietary fats impact
adipose expansion, mice were fed custom HFDs, each containing a different fat
source, and adipogenesis and hypertrophy were quantified. This screen
illustrated how dietary fats may bias the WAT toward expanding primarily through
increased adipocyte size or number. This dietary fat screen was also
instrumental in identifying oleic acid as a molecular signal inducing adipocyte
precursor (AP) activation and proliferation. Oleic acid increased adipogenesis in
vitro through Akt2 signaling and induction of lipogenesis. Using RNA sequencing
of APs from mice fed HFD, downregulation of LXRα signaling was consistently
identified in adipose tissue depots that demonstrate an adipogenic response to
HFD. LXRα phosphorylation was identified as a modulator in the proliferative
response to HFD, with dephosphorylation of LXRα resulting in enhanced dietinduced AP proliferation. This dietary fat screen also provided an effective tool to
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investigate how expression of the adipokines, adiponectin and leptin, related to
mechanisms of adipose expansion. Interestingly, VWAT expression of leptin
correlated with several measures of adipocyte formation, contrasting with its
typical association with hypertrophy. Finally, while studies using a lard-based
HFD found increased expression of inflammatory and fibrotic markers with
obesity, this screen also identified several diets that induce obesity but do not
result in increased expression of these markers. This work identifies a novel
mechanism to regulate diet-induced AP proliferation and highlights the need to
study obesity within physiologically relevant contexts.
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Chapter 1: Introduction
Obesity, defined as the expansion of white adipose tissue (WAT), is
becoming more prevalent, with 39% of the global population classified as
overweight or obese in 20151. The association of obesity with a variety of
comorbidities, including diabetes, cardiovascular disease2,3, stroke4, and cancer5,
makes this trend particularly troubling. There are many hypotheses for what has
driven this increase in obesity, including decreased physical activity, increased
availability of food, and increased popularity of processed food6,7. Given this
concerning trend, understanding mechanisms of adipose expansion and adipose
homeostasis are vital to understanding and preventing human pathologies.
In contrast to brown adipose tissue which functions in thermogenic regulation,
WAT functions as an energy reservoir, storing energy-dense lipids until times of
hunger or need. In times of caloric excess or deficit, the WAT may grow or shrink
to provide or store triacylglycerides as needed. Regulation of these processes
may be controlled by secreted hormones such as insulin, which inhibits lipolysis
and promotes lipogenesis8, or through neuronal signaling which also controls
lipolysis9. Adipose and its size are therefore at the center of energy balance,
regulating calories stored and calories burned.
In addition to its functions in energy storage and dispersal, WAT is also an
endocrine organ, capable of secreting many factors and even producing some
hormones that are specific to the adipose tissue, known as adipokines.
Adiponectin and leptin are the classic adipokines. Adiponectin exerts a variety of
functions, such as promoting insulin sensitivity10 and reducing inflammation11. In
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contrast, leptin is highly involved in energy balance, signaling satiety when
secreted at high levels, decreasing in response to fasting, and promoting energy
expenditure in lean subjects12–14. A leptin mutation is even the basis for one of
the most commonly used mouse model of obesity; the ob/ob mouse exhibits
dramatically increased food intake, resulting in a highly obese mouse that will
lose weight dramatically upon the administration of leptin15,16.
Adipose tissue is organized into distinct depots, with the inguinal
subcutaneous (SWAT) and perigonadal visceral (VWAT) adipose being the most
commonly studied in mice. These depots have many functional differences such
as rates of lipolysis17, gene expression18, and adipogenic response to a high-fat
diet (HFD)19. Preferential expansion of these two depots has been linked to
differing disease outcomes. VWAT expansion is associated with increased
likelihood of cardiovascular disease20, inflammation21, reduced angiogenic
potential22, and diabetes risk23. In contrast, further work is needed to establish
the role of SWAT in metabolic disease. While SWAT has been shown to be
weakly correlated to diabetic and cardiovascular risk compared to VWAT24, other
studies have linked this depot to a decreased risk of insulin resistance25,26.
Alternatively, rather than quantify depot size, waist-to-hip ratio is a common
method that is easy to measure and takes into account both SWAT and VWAT
depots. A higher waist-to-hip ratio has been used as a risk factor for
cardiovascular disease and mortality27. Given the different outcomes of
expanding adipose in these depots, further work is needed to elucidate how
expansion of these depots is regulated.
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Mechanisms of adipose expansion
In addition to location, adipose expansion must also be considered by its
cellular mechanisms. Adipose tissue can grow via an increase in adipocyte
number (hyperplasia) or an increase in adipocyte size (hypertrophy)28,29.
Adipocyte hypertrophy is driven by the expansion of a single lipid droplet which
can measure up to 100 µm in diameter and comprises most of the adipocyte
volume30. A major mechanism of lipid droplet expansion is the uptake of lipids,
primarily by the fatty acid (FA) scavenger, CD3631, or the insulin-sensitive FA
transporter, FATP132. A second mechanism of lipid accumulation is the
conversion of glucose to lipid via lipogenesis. This process of expansion must be
balanced by lipolysis and the utilization of lipids for energy throughout the body. If
the balance between lipid accumulation and usage is disrupted, the adipocyte
may swell dramatically, potentially resulting in a thousand fold increase in volume
and contributing to expansion of the WAT33.
During prolonged caloric excess, hypertrophy may affect the homeostasis and
function of the adipose tissue itself. Monteiro et al. used computational modeling
to demonstrate that a large adipocyte may experience more physical stress and
will be more likely to rupture with deleterious consequences34. Jo et al. also use a
combination of modeling and observational studies to determine that larger
adipocytes were more susceptible to death after prolonged HFD consumption35.
Adipocyte death results in crown-like structures, a distinctive formation of
macrophages around a dead adipocyte to clear lipid and debris. These
macrophages tend to express a pro-inflammatory cytokine profile36, linking
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adipocyte size and death to tissue inflammation. This adipose inflammation has
linked adipocyte hypertrophy to a variety of systemic metabolic consequences,
such as insulin resistance33,37,38, increased VLDL cholesterol39, and hepatic
steatosis40.
In addition to inflammation, adipose hypertrophy is associated with hypoxia,
as oxygen can diffuse 100-200 μm into tissue41, less than the diameter of the
largest adipocytes33. This hypoxia can then progress to adipose tissue fibrosis,
mediated by chronic activation of Hypoxia-inducible factor 1α and the secretion of
collagens by APs and fibroblasts42,43. Supporting this observation of progression
to fibrosis, gene expression analysis of obese SWAT in humans has identified
significant upregulation of fibrotic gene networks compared to lean, post-bariatric
surgery WAT44. However, whether this fibrotic response is detrimental or
protective is still being understood. While several studies have indicated that
fibrosis may limit adipocyte size, releasing this check upon hypertrophy often
results in decreased inflammation and improved metabolic health 45,46. These
data counter the hypothesis that hypertrophy inevitably leads to adipocyte
rupture and macrophage infiltration, indicating that regulation of adipose
homeostasis is a complex process and further understanding is needed.
Finally, in addition to inflammation and fibrosis, adipocyte hypertrophy is
linked to changes in adipokine production. Adipocyte size and obesity have been
observed to correlate negatively to plasma adiponectin concentrations 47,48. Leptin
is positively correlated to adipocyte size which has been linked to its role in
signaling fullness to the organism49,50. Many of these studies examine human
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WAT small sample sizes or quantify adipokine production in vitro. While
important, these findings should be supplemented with other studies using larger
sample sizes and quantifying adiponectin and leptin in vivo.
In contrast to adipocyte hypertrophy, which may quickly fluctuate in response
to fasting and refeeding conditions51,52, adipose hyperplasia is an enduring
change, due to the multi-year lifespan of an adipocyte53. Because adipocytes are
post-mitotic, an increase in adipocyte hyperplasia occurs by the proliferation and
differentiation of adipocyte precursors (APs). APs have been historically studied
using the immortalized pre-adipose cell line called 3T3-L1 in vitro, which
accumulates lipid when treated with an adipogenic cocktail, commonly including
insulin, dexamethasone, and methylisobutylxanthine

54,55,56.

3T3-L1s cells have

proven instrumental to understanding molecular pathways of adipogenesis. For
example, 3T3-L1 cells were employed to identify Pparγ2 which is now known as
the “master regulator” of adipogenesis57. 3T3-L1 cells were also instrumental in
identifying many other crucial transcription factors regulating adipogenesis, such
as Klf458, Krox2059, and Cebpα, Cebpβ, and Cebpδ60.
However, despite the ease of culturing and differentiating 3T3-L1 cells,
studying primary APs and in vivo models are still crucial to understanding of
adipogenesis. The adipose tissue microenvironment contains a rich variety of cell
types including mature adipocytes, neurons, endothelial cells, and immune cells
all of which impact adipocyte function and formation. For example, macrophages
have been shown to enhance adipogenesis in a 3D cell culture environment 61.
Additionally, blocking adipocyte formation in AP implants not only inhibits

5

angiogenesis, but using antibodies to block angiogenesis also inhibits
adipogenesis, indicating dual regulation of these processes62. Finally, in addition
to inter-cell crosstalk in vivo, because 3T3-L1 cells are derived from a clone54,
they will fail to capture the array of AP subtypes present in adipose tissue 63.
Therefore, in vivo studies remain important to understanding adipose tissue
regulation and growth.
In 2008, Rodeheffer et al. identified a series of cell markers which defined the
in vivo AP population64. The identity of these APs has been verified by their
ability to differentiate in vitro and to reconstitute a functional fat pad in a
lipodystrophic mouse, resulting in normalization of its blood glucose. Using flow
cytometry, these APs are defined as CD45-; CD31-; CD29+; CD34+; Sca1+, with
CD24 expression differentiating between subpopulations varying in commitment
to the adipocyte lineage65.
RNA-seq has become a valuable tool to identify alternative markers for APs
and to identify subpopulations with varying functions. For example, Merrick et al.
identified a DPP4+ population which progresses to the more committed ICAM1+
and CD142+ cells66. RNA-seq was also used to identify a population defined by
expression of LY6C and PDGFRβ, known as fibro-inflammatory progenitors, or
FIPs67. FIPs are non-adipogenic and inhibit the adipogenesis of other AP
subpopulations. The existence of a non-adipogenic subpopulation of APs is
further supported by Marcelin et al. who identified CD9 as a marker of a highly
proliferative population of APs that promote fibrosis rather than adipogenesis68.
Finally, Schwalie et al. used RNA-seq to identify the Areg population, a CD142+
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subpopulation of APs which inhibits adipogenesis in a paracrine mechanism 69.
These subpopulations indicate that APs are a diverse cell type with varying
functions. Further work will be needed to ascertain the role of these
subpopulations in WAT homeostasis.
AP function also depends on adipose depot and microenvironment. For
example, APs isolated from SWAT have greater adipogenic capacity in vitro than
do APs isolated from VWAT70. In addition, SWAT and VWAT APs differ in their
proliferative response to HFD. In male mice, VWAT APs undergo a transient
burst of proliferation at the onset of HFD feeding which then subsides to baseline
levels over the course of a week. Eight weeks later, this proliferative burst
contributes to the formation of new adipocytes. In contrast, SWAT APs in males
do not proliferate in response to HFD and do not result in hyperplasia 19. This
depot specificity is not found in female mice which exhibit an adipogenic
response to HFD in both SWAT and VWAT71; however, male mice will primarily
be used in the studies presented here. Diet-induced hyperplasia was determined
to be dependent on Akt2-signaling, in a mechanism that is specific to obesity and
HFD consumption and distinct from the adipose tissue establishment during
development. These findings illustrate the importance of studying adipose
hyperplasia in vivo within the appropriate context. These findings also illustrate
the need to identify the adipogenic stimulus in HFD consumption which this work
will address.
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Fatty acid signaling and receptors
When HFD is ingested, the lipids are packaged into chylomicrons for
transport to the various tissues. In adipose tissue, membrane proteins facilitate
the uptake of TGs into the tissue. For example, FATP1 is translocated to the
plasma membrane by insulin, where it increases lipid uptake from the plasma 32.
In addition to FATP1, CD36 is another lipid transporter, with fatty acid uptake
decreasing by 60-70% in CD30-ko mice72.
In addition to storing dietary lipids, adipocytes and APs respond to them as
signaling ligands. Dietary fats have been identified as a primary driver of
adiposity, making them a potential candidate for AP activation and proliferation73.
Fatty acids and other lipid-derived compounds known as lipokines are important
modifiers of metabolic health, able to improve insulin signaling and
hepatosteatosis74. Furthermore, fatty acids have also been shown to affect DNA
methylation and adipokine secretion in adipocytes75,76. Given the association with
obesity and HFD, additional work is needed to understanding how dietary fatty
acids impact adipose expansion and overall health.
The signaling functions of fatty acids in adipose tissue has spurred interest in
their mechanisms. Fatty acids may signal via the Free Fatty Acid Receptor
(FFAR) family, a group of G-protein coupled receptors which are categorized by
the length of fatty acid to which they bind. This work will discuss Gpr120 (also
known as FFAR4) and Gpr40 (also known as FFAR1) which bind to medium- and
long-chain fatty acids77,78. Gpr40 is primarily expressed in the pancreas and
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intestines79 and is known to mediate the effects of fatty acids on glucosestimulated insulin secretion, although whether it is harmful or beneficial has been
controversial80. Nagasumi et al. overexpressed Gpr40 in murine pancreatic beta
cells and determined that overexpression improved glucose tolerance and
glucose stimulated insulin secretion in diet-induced obese mice81. However,
Steneberg et al. found that Gpr40-/- mice were protected from obesity-associated
glucose intolerance and insulin resistance and that overexpressing Gpr40 under
the pancreatic promoter PDX1 increased hepatic steatosis and decreased
glucose tolerance and glucose-stimulated insulin secretion82. Alquier et al. have
attempted to reconcile these opposing views by noting that the PDX1 promoter
expression is not restricted to the pancreas and is also expressed in the
hippocampus. They also note that Steneberg et al.’s transgenic line may have
suffered from developmental effects, as islet morphology appeared to be
affected80. They suggest that evidence points toward Gpr40 signaling as
beneficial for metabolic health.
Unlike Gpr40, Gpr120 is known to be expressed in white adipose tissue.
Furthermore, APs with reduced expression of Gpr120 have decreased
adipogenic potential, with less lipid accumulation and decreased expression of
the adipogenic genes Pparγ-2 and aP283. Hilgendorf et al. supported the
importance of Gpr120 in adipogenesis, observing that Gpr120 are localized on
AP cilia84. Although Gpr120-/- mice consuming a long-term HFD accumulate more
adipose compared to their wild-type (WT) counterparts, embryonic fibroblasts
derived from this mouse model have reduced adipogenic potential in vitro.
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Adipocytes of these knockout obese mice are larger than WT, suggesting that
they grow preferentially by hypertrophy rather than hyperplasia in response to
diet85.
In addition to its effects on adipogenesis, Gpr120 has been studied for its
effects on inflammation and insulin resistance. Oh et al. observed that
pharmacological activation of Gpr120 reduced inflammatory gene expression in
an LPS-treated macrophage cell line, an effect that was inhibited when Gpr120
was knocked down. In addition, while supplementing a HFD with omega-3 fatty
acids improved insulin sensitivity, omega-3 fatty acids had no effect on insulin
sensitivity in Gpr120-/- mice86.
Another signaling receptor capable of responding to fatty acids is the liver X
receptor (LXR)87. This is a nuclear hormone receptor with two isoforms, α and β.
While LXRβ is expressed in most tissues, LXRα is expressed in tissues with high
lipid metabolism, such as brown and white adipose tissue, intestine, kidney, and
liver88. Published work on the role of LXRα in adipogenesis is contradictory. Seo
et al. demonstrated increased adipogenesis in 3T3-L1 cells when treated with the
LXRα activator, T0901317. Furthermore, they identified LXR binding sites in the
promoter region of the adipogenic “master regulator” Pparγ. In contrast,
Hummasti et al. did not observe any effects on 3T3-L1 differentiation when
treated with another LXRα agonist, GW396589. This difference in results could be
due to these agonists having different efficacies, with GW3965 being a weaker
agonist in some cell types90.
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While most published work has focused on LXR signaling via its ligand
binding mechanism, LXRα modulation is complex and can be regulated by its
posttranslational modifications. Torra et al demonstrated that LXRα activity
differed if it was activated via ligand binding or via dephosphorylation, with the
modulator T0901317 activating both these mechanisms91. A later study used a
mouse model containing a point mutation to induce a serine-to-alanine
conversion at residue 196 in LXRα, eliminating the phosphorylation site in a
macrophage cell line. This mutation resulted in a shift toward expression of
proliferative genes in murine bone-derived macrophages. This shift in gene
expression was determined to be independent of ligand binding by the LXRα
agonist GW396592.
This work will elucidate mechanisms of adipogenesis, including
investigating whether modulation of Gpr120, Gpr40, and/or LXRα plays a role in
AP activation by diet. This work also leverages an isocaloric HFD screen with
various fat sources, ultimately leading to the identification of a novel mechanism
of AP proliferation, the characterization of the effects of dietary fat type on WAT
gene expression and function, and greater context when considering WAT
inflammation and fibrosis during obesity. This work aims to further our
understanding of how dietary fats impact obesity while providing a quantitative
assessment of parameters related to mechanisms of adipose expansion.
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Chapter 2: Dietary oleic acid induces AP proliferation via down-regulation
and dephosphorylation of LXRα
Results
Effects of dietary fats on adipose hypertrophy and hyerplasia
Jeffery et al. determined that adipose hyperplasia induced by HFD is a
distinct process from hyperplasia to establish the WAT during development.
However, the mechanism of diet-induced obesity remained unknown. To
determine whether diet activation of APs is due solely to increased caloric intake,
AP proliferation was quantified in mice pair-fed HFD to calorically matched mice
fed a standard diet (SD) for 1 week.
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Figure 1: Dietary fat source determines whether VWAT expands primarily via
hypertrophy or hyperplasia. A) VWAT AP proliferation in mice fed SD or pair-fed HFD
mice for 7 days. (n=5; unpaired t-test; experiment conducted by Christopher Church) B)
AP proliferation in SWAT and VWAT normalized to the SD-fed VWAT proliferation. Mice
were fed the indicated HFD for 7 days. (n=5-2; experiment conducted by Jennifer
Kaplan) C) VWAT weights of mice which consumed the indicated HFD for 12 weeks
13

(n=4-5; measured by Jennifer Kaplan) D) Quantification of newly formed adipocytes from
AdiCre-ER/mTmG mice. Mice were injected with tamoxifen then given indicated HFD for
8 weeks. (n=3-18) E) Quantification of VWAT BrdU-labeled adipocyte nuclei. Mice were
given indicated HFD with BrdU water for one week. BrdU water was then removed, and
mice continued to consume indicated diet for a total of 12 weeks. (n=4-5). F) Mean
VWAT adipocyte volume from mice which consumed the indicated HFD for 12 weeks.
(n=4-5). Correlations between VWAT mass and G) average VWAT adipocyte diameter
for each diet and H) average rate of adipocyte formation for each diet. (Significance
calculated by one-way ANOVA multiple comparisons to SD or Spearman correlation)

Although both sets of mice consumed the same number of calories, VWAT APs
of HFD-fed mice had increased proliferation compared to APs of SD-fed mice
(Figure 1A). These results indicate that AP activation by diet is not due solely to
increased caloric intake, suggesting that composition of the diet itself drives AP
proliferation.
Increased dietary fat has been found to be more strongly associated with
obesity compared to dietary carbohydrate and protein content93. To determine if
dietary fat sources impact adipogenesis, we designed a series of identical,
isocaloric 45% fat diets with varying fat sources. Mice were fed these diets for
one week along with drinking water containing BrdU to quantify AP proliferation.
After one week, VWAT APs demonstrated a highly varied response to the HFDs,
with some diets such as Fish and Palm inducing no significant change in AP
proliferation while Soybean and Peanut resulted in an increased proliferation
(Figure 1B). SWAT AP proliferation was not significantly increased compared to
SD. These data indicate that dietary fat source and composition are highly
relevant to AP activation and proliferation.
I next wanted to characterize the effects of these dietary fats on WAT
expansion. WT mice that consumed the diets for 12 weeks demonstrated
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variations in VWAT mass, with most diets increasing VWAT mass to varying
degrees while other diets such as High Oleic (HO) Sunflower and HO Safflower
did not increase VWAT compared to SD (Figure 1C). To determine whether diets
that induced AP proliferation also resulted in increased adipocyte formation, diets
were fed to the AdiponectinCre-ER/mTmG (AdiCre-ER/mTmG) mouse model for
8 weeks to quantify adipogenesis as presented preivously94. In brief, this model
utilizes an inducible Cre response element regulated by the adiponectin promoter
so that upon induction, adipocytes transition from expressing a red fluorescent
reporter to a green one. When mice are fed the indicated HFD, any adipocytes
that form after induction will be red, allowing for the quantification of in vivo
adipogenesis. In addition to increased AP proliferation, the Lard, Olive, and
Soybean diets resulted in increased adipocyte formation compared to SD (Figure
1D). However, HO Sunflower, HO Safflower, and Peanut diets which resulted in
the most extreme increase in AP proliferation, resulted in lower rates of
adipogenesis than expected and were not significantly increased. As an
alternative measure of adipogenesis, I performed a BrdU pulse-chase to quantify
BrdU-labeled adipocytes formed from diet-activated APs. In brief, mice were
given the HFD and BrdU drinking water for one week. The BrdU was then
removed, and the mice continued to consume the diet for 11 more weeks,
allowing any activated APs to differentiate and form mature adipocytes. In this
case, none of the diets resulted in a significant increase above SD within the
context of the diet series (Figure 1E). However, these data appeared to mimic
trends from the AdiCre-ER/mTmG mice with Lard, Olive, and Soybean having
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more BrdU-labeled nuclei and HO Sunflower, HO Safflower, and Peanut having
fewer labeled nuclei. Therefore, in addition to driving different rates of AP
proliferation, dietary fat source affects adipocyte formation as well.
Adipocyte size was quantified by staining fixed sections of adipose tissue
with Masson’s trichrome stain and systemically imaging and quantifying
adipocyte area. Interestingly, upon quantifying VWAT adipocyte volume,
relatively few diets resulted in increased adipocyte size compared to SD. Yet
diets with low adipocyte formation such as Butter and Palm diets had the most
dramatic increases in adipocyte size. In contrast, diets resulting in greater
adipocyte formation such as Olive and Soybean did not significantly increase
adipocyte size (Figure 1F). These data suggest that dietary fat source may bias
the tissue toward expanding primarily via hypertrophy or hyperplasia.
In previously published work, comparing fat mass gain during
consumption of a 60% lard HFD to SD consumption illustrated that both adipose
hypertrophy and hyperplasia contribute to overall WAT mass71,95. However, we
have used a series of HFDs, resulting in a variety of graded responses in fat
mass gain. This approach allows us to separate and distinguish between these
mechanisms to assess their effects on overall adipose mass. Quantifications of
adipogenesis and adipocyte diameter from the dietary fat screen were correlated
to each individual mouse’s VWAT mass. While adipocyte diameter had a strong
and significant correlation to VWAT mass, adipogenesis demonstrated no such
correlation, suggesting that in the more complex context of the dietary fat screen,
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adipocyte size is a stronger driver of depot size than is adipogenesis (Figure 1GH).

Figure 2: SWAT lacks an adipogenic response to HFDs and expands primarily via
hypertrophy. A) SWAT mass after 12 weeks of diet consumption. (n=5; measured by
Jennifer Kaplan) B) Quantification of newly formed SWAT adipocytes in AdiCreER/mTmG mice after 8 weeks of HFD consumption. (n=3-18) C) Quantification of
proportion of BrdU-labeled SWAT adipocyte nuclei in mice which ate diet for 12 weeks.
(n=4-5) D) Mean SWAT adipocyte volume after 12 weeks of consuming indicated HFD.
(n=4-5). Correlations between SWAT mass and E) SWAT adipocyte diameter and F)
SWAT adipocyte formation in AdiCre-ER/mTmG mice. (Significance calculated by oneway ANOVA multiple comparisons to SD or Spearman correlation)
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In characterizing the WT SWAT mass after long-term consumption of
indicated HFD, this tissue demonstrated a range of responses, with some strong
increases in SWAT weight in diets such as Palm and Peanut and some moderate
increases, such as during Palm consumption (Figure 2: SWAT lacks an
adipogenic response to HFDs and expands primarily via hypertrophy. A) SWAT
mass after 12 weeks of diet consumption. (n=5; measured by Jennifer Kaplan) B)
Quantification of newly formed SWAT adipocytes in AdiCre-ER/mTmG mice after 8
weeks of HFD consumption. (n=3-18) C) Quantification of proportion of BrdU-labeled
SWAT adipocyte nuclei in mice which ate diet for 12 weeks. (n=4-5) D) Mean SWAT
adipocyte volume after 12 weeks of consuming indicated HFD. (n=4-5). Correlations
between SWAT mass and E) SWAT adipocyte diameter and F) SWAT adipocyte
formation in AdiCre-ER/mTmG mice. (Significance calculated by one-way ANOVA
multiple comparisons to SD or Spearman correlation)A). In contrast to VWAT, SWAT

adipocyte formation in the AdiCre-ER/mTmG mice was not significantly
increased compared to SD on the various HFDs (Figure 2B). Additionally,
although there was variation in the proportion of BrdU-labeled SWAT adipocyte
nuclei, none of the diets resulted in significantly greater adipogenesis compared
to SD by this measure of hyperplasia (Figure 2C). Finally, like VWAT, 12 weeks
of consuming the various HFDs resulted in varying SWAT adipocyte sizes with
the Lard and Butter diets inducing significantly increased adipocyte size
compared to SD (Figure 2D). Also, similarly to VWAT, SWAT mass was
significantly correlated to adipocyte size rather than adipocyte formation (Figure
2E-F). These data indicate that while there are depot-specific differences in how
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dietary fats activate mechanisms of WAT expansion, hypertrophy remains the
primary overall driver.
Dietary oleic acid promotes AP proliferation and adipogenesis

Figure 3: Dietary oleic acid drives AP proliferation and differentiation. A)
Correlation between dietary oleic acid content and average fold increase in VWAT AP
proliferation after one week of diet consumption. (Spearman correlation) B) Total plasma
fatty acid concentration during first week of 60% lard HFD consumption. (n=5; unpaired
t-test) C) Percentage change in plasma oleic acid concentration compared to Day 0 of
HFD consumption. (n=5; unpaired t-test) D) Oleic acid content in VWAT during HFD
feeding. (n=3, unpaired t-test E) Fat pad mass of mice which consumed SD with vehicle
or SD supplemented with tri-oleate to 45% for 8 weeks (n=5; one-way ANOVA) F) AP
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proliferation in SWAT and VWAT after one week of SD supplemented with vehicle or trioleate. (n=5; one-way ANOVA) G) VWAT AP proliferation after 5 days of SD
supplemented with purified fatty acids. (n=5; one-way ANOVA) H) AP proliferation after
daily jugular infusions of oleic acid (20 mM) or vehicle (BSA) for 5 days. (n=5; one-way
ANOVA) I) Lipid accumulation quantified by Oil Red O staining after 7 days of
differentiation of primary APs. APs differentiated with insulin, insulin supplemented with
indicated fatty acid (100 µM), or MDI. (n=3; one-way ANOVA compared to insulin) J)
Lipid accumulation in primary human APs differentiated with MDI or MDI supplemented
with oleic acid (100 µM) for 7 days. Human APs defined as CD45-; CD235-, CD90+,
GP38+, and CD34+. (n=3; unpaired t-test) (All experiments conducted by Christopher
Church)

To determine mechanistically how dietary fats drive mechanisms of
adipose expansion, lipidomic analysis was performed to determine the fatty acid
composition of each diet. In correlating fatty acid composition to measures of
hypertrophy and hyperplasia, oleic acid was found to be significantly and strongly
correlated to AP proliferation (Figure 3A). This relationship contrasted with other
fatty acids, such as 16:0, 18:0, and 18:2n-6, which are similar in structure and
demonstrated no such correlation (data not shown). Previous studies have
shown that AP proliferation peaks at Day 3 of HFD and subsides back to basal
proliferation after the first week19. In quantifying plasma and adipose fatty acids
after 3 or 7 days of a 60% lard-based HFD, total plasma fatty acids peaked at
Day 3 and were decreased on Day 7 (Figure 3B). Plasma oleic acid mimicked
the plasma fatty acid levels, increasing on Day 3 and decreasing on Day 7
(Figure 3C). In contrast, VWAT oleic acid increased steadily over the course of
the week (Figure 3D). These results suggest that the decrease in plasma oleic
acid and fatty acids is due to the absorption by WAT. These findings identify oleic
acid as a potential nutritional signal driving in vivo AP proliferation.
To determine whether oleic acid induces AP proliferation or is merely
correlated with it, SD was supplemented with tri-oleate, a more stable form of
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oleic acid. These diets were supplemented to 45% kcal fat, matching the custom
diet series. Long-term consumption of this supplemented diet was sufficient to
increase VWAT mass, while there was no effect on SWAT mass (Figure 3E).
When mice were fed these diets for one week, the addition of tri-oleate was
sufficient to induce a significant increase in AP proliferation in the VWAT, while
there was no effect in the SWAT (Figure 3F). As another approach to this
experiment, stearic acid (18:0), oleic acid (18:1), and linoleic acid (18:2) were
directly supplemented into a SD. Of these fatty acids, only oleic acid induced AP
proliferation in the VWAT, while stearic and linoleic acids were no difference than
SD (Figure 3G). To determine whether oleic acid itself or a metabolite formed
during absorption is responsible for inducing AP proliferation, mice were given
jugular catheters to allow oleic acid to be administered directly into the blood
stream. In this scenario, oleic acid was still sufficient to increase AP proliferation
in VWAT (Figure 3H). These data show that dietary oleic acid is sufficient to
induce AP proliferation in vivo.
To further characterize the specificity of oleic acid in driving adipose
hyperplasia, primary APs were harvested and cultured in vitro. The cells were
then differentiated using either insulin, an adipogenic cocktail of insulin,
dexamethasone, and 3-isobutyl-1-methylxanthine (MDI), or insulin supplemented
with a screen of fatty acids. Of the fatty acid screen, only oleic acid (C18:1) and
palmitoleic acid (C16:1) resulted in significantly more lipid accumulation (Figure
3I). We also observed from our lipidomic data that the concentration of fatty acid
used was physiologically relevant for oleic acid but was hyper-physiologic for
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palmitoleic acid, suggesting that oleic acid remains a highly specific driver of
adipogenesis. Finally, to determine whether oleic acid also increased lipid
accumulation in human APs, we isolated primary APs from human adipose
samples and differentiated them in the presence of oleic acid. Oleic acid
significantly increased lipid accumulation (Figure 3J), suggesting this effect is not
restricted to mice. These data show that oleic acid is capable of inducing
adipogenesis in addition to AP proliferation.
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Figure 4: OA increases adipogenesis by inducing Akt2 activation and lipogenesis.
A) Lipid accumulation in primary APs sorted from WT or Akt2-/- mice differentiated with
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insulin, MDI, or insulin supplemented with oleic acid (18:1; 100 µM) for 7 days. (n=3;
one-way ANOVA) B) Immunoblot and quantification of Akt2 phosphorylation at Serine
473 (S473) in primary APs after 3 hours of differentiation with insulin or insulin
supplemented with oleic acid (18:1; 100 µM). (unpaired t-test) Gene expression of C)
Pparγ, D) Cebpα, E) adiponectin, F) leptin, G) Fabp4, and H) perilipin in primary WT or
Akt2-/- APs after 12 hours of differentiation with insulin or insulin supplemented with oleic
acid (n=3; one-way ANOVA) I) Lipid accumulation in primary APs after 24 hours of
differentiation with insulin, or insulin and oleic acid (OA; 100µM) with glucose uptake
inhibitor or fatty acid synthase inhibitor. (± 25 mM glucose as indicated; n=3; unpaired ttest) (All experiments performed by Christopher Church)

Jeffery et al. found that Akt2 signaling is required for diet-induced
adipogenesis yet is not required for hyperplasia during adipose establishment
and development. To determine whether the ability of oleic acid to induce AP
differentiation is dependent on Akt2, lipid accumulation was quantified in Akt2-/APs. While oleic acid significantly increased lipid accumulation in the WT cells,
this increase was ablated in the Akt2-/- cells (Figure 4A). To quantify Akt2
activation during oleic acid treatment, phosphorylation of residue S473 was
quantified. After 3 hours of differentiation, oleic acid supplementation resulted in
significantly more Akt2 activation than insulin alone (Figure 4B). In addition to
lipid filling, Akt2 is also required for the characteristic changes in gene expression
that accompany adipogenesis. While WT APs increased expression of Pparγ,
Cebpα, adipongectin, leptin, Fabp4, and perilipin in response to oleic acid, Atk2 -/APs failed to increase expression of these genes during differentiation (Figure
4C-H). These data indicate that oleic acid acts in a signaling mechanism to
activate Akt2 and suggests that oleic acid is a dietary ligand that promotes
adipogenesis.
AP proliferation is mediated by LXRα signaling
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Figure 5: Oleic acid decreases LXRα activity and phosphorylation. A) Heat map
showing pathways which are up- or downregulated in sorted APs in response to 3 days of
60% lard HFD consumption (n=3-5). VWAT expression of B) LXRα and C) Srebp-1c
after 3 days of SD or HFD consumption. (n=5) D) LXR activity quantified by a luciferase
reporter assay in 3T3-L1s after 24 hours treatment with MDI, MDI with oleic acid (OA;
100 µM), or MDI with T0901317 (5 µM). (n=6) E) Dephosphorylation of LXRα is
associated with upregulation of genes involved in proliferation. F) Western blot and
quantification of p-LXRα in primary APs differentiated for 24 hours with insulin or insulin
supplemented with oleic acid (OA; 100 µM), linoleic acid (LA; 100 µM), or T0901317 (5
µM). (n=1) (Significance calculated by unpaired t-test)
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To identify a mechanistic pathway for how dietary oleic acid induces AP
proliferation, I used our understanding of sex-dependent differences in WAT
patterning. While male mice undergo diet-induced adipogenesis in the VWAT96,
HFD induces adipogenesis in the SWAT and VWAT of female mice (Appendix
Figure 18). I used an RNA-seq dataset collected from the SWAT and VWAT APs
of male and female mice fed either SD or 60% lard HFD for 3 days, the time of
maximal diet-induced AP proliferation96. I analyzed this dataset for pathways
modulated by HFD that were consistent between the adipogenic depots—male
VWAT and female SWAT and VWAT—and lacking in the nonadipogenic depot—
male SWAT. Downregulation of the LXR/RXR pathway was identified to be a
strong hit fulfilling these criteria (Figure 5A). Of the LXR isoforms, LXRα was of
particularly interest given its role in activating genes involved in lipogenesis and
cholesterol transport97. LXRα is also known to be involved in oleic acid signaling,
modulating oleic acid-induced hepatic lipogenesis98, and protecting against oleic
acid-induced pulmonary inflammation99.
To verify the results of the RNA-seq pathway analysis, APs were sorted
from SWAT and VWAT of male mice fed either SD or 60% HFD for 3 days. Gene
expression of LXRα and other genes downstream of LXRα signaling was then
quantified. Interestingly, there was no change in expression of LXRα itself (Figure
5B). However, expression of Srebp-1c, a gene regulated by LXRα signaling was
decreased in the HFD SWAT and trending toward decreased expression in the
VWAT (Figure 5C). These data suggest that while LXRα expression was not
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affected, at least one of its downstream signaling pathways was downregulated,
consistent with the RNA-seq dataset.
To determine whether LXRα activity was being modulated specifically by
oleic acid, 3T3-L1s were transfected with a luciferase reporter to quantify LXR
activity. Cells were also treated with the LXRα modulator T0901317 as a positive
control. While the T0901317 resulted in a strong increase in LXR activity,
supplementation of oleic acid in the adipogenic cocktail significantly decreased
LXR activity relative to MDI alone (Figure 5D). As LXRα expression was not
affected by short-term HFD consumption, we considered posttranslational
modifications as an alternative mechanism of regulation. The modulator
T0901317 has been shown to increase LXRα phosphorylation91. Furthermore,
dephosphorylation of LXRα has been found to promote expression of
proliferative genes in bone-derived macrophages (Figure 5E)92. The mechanisms
of this signaling are still being understood. To determine whether oleic acid
affects LXRα phosphorylation, primary APs were cultured and differentiated for
24 hours. Treatment with oleic acid slightly decreased LXRα phosphorylation,
while treatment with linoleic acid and T0901317 resulted in increased LXRα
phosphorylation (Figure 5F). While this experiment will be repeated in the near
future, these data suggest that oleic acid decreases LXRα activity and its
phosphorylation, which could increase proliferation of the cells.
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Figure 6: LXRα phosphorylation is inhibitory to VWAT diet-induced AP
proliferation. A) AP proliferation in mice given 60% Lard HFD and daily injections of
vehicle (MCT) or T0901317 (50 mg/kg) for 3 days with BrdU drinking water. (n=5) B)
Quantification of the percentage of APs (Sca1+ cell) which are p-LXRα+. (n=4-5)
Quantification of C) VWAT and D) SWAT AP proliferation measured by Ki67 expression
in WT (C5Bl/6J) or S196A LXRα mice after 3 days of SD or HFD consumption. (n=5-6)
(Significance measured by unpaired t-test)

To quantify how modulation of LXRα signaling affects AP proliferation in
vivo, mice were treated with T0901317 along with 3 days of 60% lard HFD
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feeding. While T0901317 did not affect AP proliferation relative to vehicle in the
SWAT over this time course, it led to a decrease in VWAT AP proliferation
(Figure 6A). This depot specificity suggests that LXRα activation prevents dietinduced AP proliferation.
To determine how LXRα phosphorylation is affected by short-term HFD
consumption in vivo, immunohistochemistry was used to stain VWAT with Sca1
to mark APs and p- LXRα. The proportion of APs with phosphorylated LXRα was
then quantified in mice fed SD or HFD for 3 days. Short-term HFD consumption
resulted in decreased APs with phosphorylated LXRα (Figure 6B). Finally, to
determine whether decreased LXRα phosphorylation is involved in diet-induced
AP proliferation, mice with a serine-to-alanine mutation at an LXRα
phosphorylation site (S196A) were obtained. These mice were fed SD or 60%
lard HFD for 3 days. VWAT AP proliferation in the S196A mice was not affected
when the mice consumed SD. However, when the mice were given HFD, VWAT
AP proliferation in the S196A mice was strongly induced and was significantly
greater than AP proliferation in the HFD-fed WT mice (Figure 6C). This finding
indicates that LXRα phosphorylation is inhibitory to diet-induced AP proliferation
but does not affect basal VWAT proliferation. Interestingly, in the SWAT, while
there was no diet-induced AP activation, proliferation in the SD- and HFD-fed
S196 mice were significantly increased over the WT proliferation, suggesting that
LXRα phosphorylation may be also be involved in inhibiting the proliferative
response in SWAT (Figure 6D). These data show that LXRα phosphorylation
inhibits diet-induced AP proliferation.
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Discussion
Using a matched series of HFDs, we have shown that the type of dietary fat
influences whether adipose expands primarily through hyperplastic or
hypertrophic mechanisms, or both. This HFD screen identifies oleic acid as a
dietary driver of AP proliferation that increases Akt2 phosphorylation and
lipogenesis. Finally, I have also identified LXRα phosphorylation as an inhibitory
mechanism of diet-induced AP proliferation.
Many other studies have illustrated the significant role fatty acids play in
regulating adipose phenotypes, such as inflammation 100, adiposity 101, and
insulin signaling 102. However, we utilized a series of isocaloric HFDs that are
identical except for the fat sources, allowing us to focus on the in vivo effects of
dietary fats without being confounded by differing carbohydrates and proteins
between the diets. Furthermore, the use of several HFDs, as opposed to
comparing a low-fat diet to HFD, has yielded more graded responses, allowing
the identification of trends that may otherwise be obscured by studying two
extremes in fat content. For example, while we have previously shown that
adipogenesis correlates with adipose depot weight when comparing SD to a 60%
HFD 103, our approach allowed us to define a more nuanced context of many
HFDs in which adipocyte size was found to be more tightly linked to depot
weight.
Using correlations between dietary fatty acid composition and measures of
adipose expansion, oleic acid was identified as a dietary signal inducing AP
activation and proliferation. The primary source of oleic acid in the human diet is
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olive oil, which is a major component of the Mediterranean diet. In addition to its
association to decreased cardiovascular disease and cancer risks

104,105,

the

Mediterranean diet has also been studied as a potential therapy for weight
loss106,107. In other studies, it has been praised as a palatable, non-obesogenic
diet, despite its high proportion of fat, primarily comprising of olive oil

108–110.

Therefore, it is perhaps surprising that our findings identify oleic acid as a dietary
driver of AP proliferation. However, Mediterranean diet is characterized by
several other parameters, including high consumption of fruits, vegetables,
legumes, and unrefined cereals and grains which can also have benefits on
health 111. Additionally, although oleic acid is a major component of olive oil, extra
virgin olive oil, a healthier variation of refined olive oil, also contains many other
compounds such as polyphenols and vitamins. In particular, polyphenols have
been identified as the potential drivers of the cardiovascular and inflammatory
benefits of olive oil 112–114. Therefore, this identification of oleic acid as a dietary
signal inducing AP activation is not necessarily inconsistent with the
Mediterranean diet’s association with longevity.
Furthermore, lipodystrophic models illustrate the dire consequences to
metabolic health in the absence of adipose, indicating that some adipose tissue
is necessary to store and manage lipids 115,116. This metabolic phenotype can
even be reversed with the addition or reinstallation of white adipose tissue 64,117.
The overflow model expands upon this idea, identifying adipose tissue expansion
as a compensatory mechanism to sequester lipids away from ectopic storage
such as in muscle and liver 118–120. Furthermore, the formation of many, small
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adipocytes has been related to improved insulin sensitivity and metabolic health
38,121.

Adipogenesis is also a hypothesized mechanism behind thiazolidinediones,

a class of Ppar-γ agonists that improve insulin resistance, but are associated with
adipose gain through adipogenesis 122–124. Further work on mice consuming this
HFD series will be able to reveal whether dietary oleic acid is associated with any
metabolic pathologies.
Our data finds that oleic acid promotes adipogenesis via Akt2 signaling
and stimulation of lipogenesis. These data also make the novel discovery of
LXRα phosphorylation as a regulatory mechanism to inhibit AP proliferation.
Knockout of LXRα in adipose tissue has been published to result in substantially
increased fat mass and larger adipocyte size125. Additionally, prolonged
treatment of ob/ob mice with the LXRα agonist GW3965 resulted in redistribution
of adipose tissue shifting from VWAT to SWAT but did not alter adipocyte size or
number126. However, while these mouse models target expression of LXRα or
activate it via ligand binding, our hypothesis addresses modulation of LXRα
signaling via its dephosphorylation. The mechanism of LXRα activation, whether
through ligand or posttranslational modification, regulates its downstream activity
and signaling91,92. I observed high basal rates of LXRα phosphorylation in VWAT
APs, consistent with the low basal rates of AP proliferation during SD
consumption. Additionally, I observed increased VWAT AP proliferation during
HFD consumption, but no effect on AP proliferation of SD-fed mice, suggesting
that the S196A mutations affects diet-induced proliferation, rather than basal
proliferation. These data identify a novel mechanism to regulate AP proliferation
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in response to HFD. Further work should be done to determine whether LXRα
phosphorylation also plays a role in AP differentiation or if it is solely involved in
AP activation.
Our HFD series has illustrated the significant influence dietary fats play in
mechanisms of adipose expansion. We have also identified oleic acid as a
dietary fatty acid capable of inducing AP proliferation and lipogenesis. Other fatty
acids should be studied to determine whether they mediate the many other
health disorders associated with obesity. I have identified LXRα phosphorylation
as a novel regulator of AP activation. The ability of this HFD series to bias
adipose tissue expansion toward hypertrophy or hyperplasia provides a tool to
understand how these mechanisms relate to metabolic pathologies associated
with obesity.
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Chapter 3: Gpr120 and Gpr40 are not required for diet-induced AP
proliferation
Results
Gpr120 and Gpr40 do not mediate diet-induced AP proliferation
With the identification of dietary oleic acid as a driver of AP proliferation, I
was motivated to consider potential receptors that could mediate oleic acid
signaling, which led me to focus on Gpr120 and Gpr40. These receptors belong
to the Free Fatty Acid Receptor family and are activated by medium- to longchain fatty acids77,127,128. While Gpr40 has primarily been studied for its role in
insulin-stimulated glucose secretion in the pancreas129, Gpr120 is expressed in
WAT, and has been shown to promote differentiation of 3T3-L1 cells83. However,
in vivo work on the role of Gpr120 in adipogenesis has been limited.
To determine the effects of Gpr120 and Gpr40 on adipose hyperplasia, we
obtained whole-body Gpr120-knockout (Gpr120KO) and Gpr40-knockout
(Gpr40KO) mice. To verify the knockout and ensure that knockout of one
receptor did not result in a compensatory increase in expression of the other
receptor, I quantified gene expression in these mice.

Figure 7: Expression of Gpr40 and Gpr120 does not increase in the knockout of
the other receptor. A) Expression of Gpr40 in sorted SWAT and VWAT APs from WT,
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Gpr120KO, and Gpr40KO mice. (n=3) B) Expression of Gpr120 in sorted SWAT and
VWAT APs from WT, Gpr120KO, and Gpr40KO mice. (n=3; two-way ANOVA)

The Gpr40KO mice demonstrated highly efficient knockout of Gpr40 expression
in both the SWAT and VWAT (Figure 7A). Expression of Gpr120 was also nearly
eliminated in the Gpr120KO mice in both SWAT and VWAT (Figure 7B).
Interestingly, Gpr40 expression was also decreased in the Gpr120KO VWAT.
These data indicated that the knockout mouse models were highly efficient and
did not result in compensatory overexpression of the opposite receptor.
Previous work in the lab quantified proliferating APs in whole-body Gpr120
or Gpr40 knockout mice. After 3 days of HFD consumption, while proliferation in
VWAT of Gpr120KO APs was similar to that of WT mice, proliferation in VWAT
Gpr40KO APs was decreased compared to WT mice. These data initially
identified Gpr40 as a potential mediator of diet-induced AP proliferation.
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Figure 8: Gpr40 and Gpr120 are not required for diet-induced AP proliferation.
VWAT AP proliferation in WT and Gpr40KO mice fed HFD for 7 days. (n=4-16) B) VWAT
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AP proliferation in WT and Gpr120KO mice fed HFD for 7 days. (n=7-8) C) SWAT AP
proliferation in WT and Gpr40KO mice fed HFD for 7 days. (n=4-16) D) SWAT AP
proliferation in WT and Gpr120KO mice fed HFD for 7 days. (n=7-8) E) VWAT AP
proliferation in Gpr40Het/Gpr120KO, Gpr40KO/Gpr120Het, or Gpr40KO/Gpr120KO
mice fed HFD for 7 days (n=2-10) F) SWAT AP proliferation in Gpr40Het/Gpr120KO,
Gpr40KO/Gpr120Het, or Gpr40KO/Gpr120KO mice fed HFD for 7 days. (n=2-10) G)
VWAT AP proliferation in WT or Gpr40KO mice fed HFD for either 3 days or 6 days.
(n=4-5) H) Proliferation of injected (Donor) or endogenous WT APs or Gpr40KO APs
which were transplanted into the VWAT of WT mice which was then fed HFD for 7 days.
(n=6) (Significance calculated by unpaired t-test)

To repeat this result, I subjected Gpr120KO and Gpr40KO mice to our typical
assay of one week of HFD19. In contrast to previous results, in the VWAT, both
Gpr120KO and Gpr40KO mice exhibited increased AP proliferation when HFDfed compared to Chow-fed knockouts (Figure 8A-B). As expected for male mice,
neither the Gpr40KO or Gpr120KO mice demonstrated diet-induced AP
proliferation in the SWAT (Figure 8C-D). As these receptors bind to similar
ligands, one hypothesis was that the two receptors may act redundantly. To
address this idea, I bred mice that lacked both the Gpr120 and Gpr40 receptors.
However, when these mice were fed a HFD for one week and compared to their
heterozygous littermates, there was no still difference in VWAT AP proliferation
(Figure 8E). Again, as expected, there was no difference in the SWAT AP
proliferation in HFD-fed double-knockout mice compared to heterozygous
littermates (Figure 8F). These data indicate that neither Gpr120 nor Gpr40 are
required for diet-induced AP proliferation.
Gpr40 mediates secretion of intestinal hormones, such as cholecystokinin
which aids in digestion of fats and proteins130. This role in lipid digestion could
impact the timing of fatty acid absorption and could contribute to the apparent
discrepancies between previous data in which decreased AP proliferation in
Gpr40KO mice was observed and my results that fail to detect any effect. To test
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this hypothesis, I quantified AP proliferation during 0-3 days and 3-6 days of HFD
consumption. There was no significant induction of AP proliferation during days
0-3 of HFD, explaining how our initial, 3 day experiment identified Gpr40 deletion
as inhibitory to AP proliferation. However, during 3-6 days, AP proliferation was
strongly induced in the Gpr40KO mice, even compared to WT mice, suggesting
that AP proliferation is not inhibited but merely delayed in these mutant mice
(Figure 8G).
To remove the effects of this delayed response, we sought to determine
whether AP-intrinsic expression of Gpr40 impacted hyperplasia by performing
cell transplants as detailed in Jeffery et al131. In brief, Gpr40KO mice were
crossed to mTmG mice, causing all cells to express the red fluorescent protein
Tomato in their membranes. APs were harvested from these mice and injected
into the VWAT of B6 mice, whose cells lacked the Tomato expression. In
comparing the proliferation of the endogenous, WT cells and the donated,
Gpr40KO cells, there was no difference in proliferation between either of these
cell types (Figure 8H). These data demonstrate that AP expression of Gpr40 is
not required for a proliferative response to HFD.
Gpr40 and Gpr120 do not affect adipose hypertrophy or hyperplasia
While Figure 8 indicates that Gpr120 and Gpr40 were not required for a
proliferative response to HFD, these receptors could nonetheless affect
subsequent differentiation after the activation phase. To test this idea, I fed HFD
to Gpr120KO and Gpr40KO mice for 8 weeks.
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Figure 9: Knockout of Gpr40 and Gpr120 does not affect adipocyte hyperplasia or
hypertrophy. A) Body weights over time of WT or Gpr40KO mice fed SD or HFD for a
total of 8 weeks. (n=5-6) B) Body weights over time of WT or Gpr120KO mice fed SD or
HFD for a total of 8 weeks. (n=4-5; multiple t-test comparing Gpr40KO HFD to WT HFD)
C) Mass of VWAT from WT or Gpr40KO mice. D) Mass of VWAT from WT or Gpr120KO
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mice fed SD or HFD. E) Mass of SWAT from WT or Gpr40KO mice fed SD or HFD. F)
Mass of SWAT from WT or Gpr40KO mice fed SD or HFD. G) Percentage of BrdUlabeled adipocyte nuclei in VWAT of WT or Gpr40KO mice fed HFD for 8 weeks. H
Percentage of BrdU-labeled adipocyte nuclei in VWAT of WT or Gpr120KO mice fed
HFD for 8 weeks. I) Average adipocyte volume in VWAT of WT or Gpr40KO mice fed
HFD for 8 weeks. J) Average adipocyte volume in VWAT of WT or Gpr120KO mice fed
HFD for 8 weeks

While the Gpr40KO mice were not heavier than the WT mice on both HFD
and Chow (Figure 9A), the HFD-fed Gpr120KO mice were significantly heavier
than the HFD-fed WT mice (Figure 9B). This difference becomes significant at 3
weeks of HFD consumption which is earlier than the 8 weeks needed to for
activated APs to differentiate. Interestingly, while the HFD-fed Gpr40KO mice
consumed similar quantities of food to the HFD-fed WT mice (Figure 9C), the
HFD-fed Gpr120KO mice consumed more calories during the initial period of diet
consumption (Figure 9D). When quantifying depot weight, while the VWAT of the
Gpr120KO and Gpr40KO mice were similar to WT mice (Figure 9E-F), the SWAT
of the HFD-fed Gpr120KO mice was heavier than the SWAT of the WT mice
(Figure 9E-H). The SWAT of the HFD-fed Gpr40KO mice was not statistically
increased from the SWAT of the WT mice. This characterization of these
knockout mice indicates that while there are slight differences in the Gpr120KO
body weights and SWAT, there is no difference in the mass of the adipogenic
depot, the VWAT, in either of these knockouts.
To determine whether these receptors impact adipogenesis, I performed a
BrdU pulse-chase as presented previously19. In brief, mice were given BrdU
drinking water along with HFD for one week after which the BrdU was removed,
and the mice continued to consume HFD for a total of 8 weeks. This assay
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allows quantification of APs that were activated to differentiate by the HFD. After
8 weeks of HFD, there was no difference in the proportions of BrdU-labeled
adipocyte nuclei in either HFD-fed Gpr120KO or Gpr40KO mice compared to WT
mice (Figure 9I-J). Finally, to determine whether knockout of Gpr120 or Gpr40
impacted adipose hypertrophy, I quantified adipocyte volume from confocal
microscopy images taken of stained tissue. There was no statistically significant
difference between the volumes of VWAT adipocytes in WT and Gpr120KO or
Gpr40KO mice (Figure 9K-L), indicating that. These data indicate that Gpr120
and Gpr40 do not affect adipose hypertrophy or hyperplasia.

Discussion
Given the work identifying dietary oleic acid as a driver of AP proliferation,
we sought to identify receptors that mediate this signaling. However, using a
variety of assays, my studies clearly demonstrate that Gpr120 or Gpr40 do not
exert strong influences on AP proliferation or differentiation.
Previous works have suggested that knockout of Gpr120 reduces
adipogenesis132, while treatment with small molecule Gpr120 agonists increase
in vitro adipogenesis133,134. However, these studies have been in vitro, using
either primary cells or the adipocyte precursor cell line 3T3-L1. In contrast, in
using a whole-body knockout of Gpr120, there was no impact on in vivo AP
proliferation or differentiation. Given that our mouse model was a whole-body
knockout, perhaps a more targeted knockout only in APs would reiterate the
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results observed in vitro. Nonetheless, our data demonstrate the need to verify in
vitro findings in vivo.
Ichimura et al. identified that knockout of Gpr120 exacerbates diet-induced
obesity, with Gpr120KO mice exhibiting increased fat mass and adipocyte area
when consuming either SD or HFD132. While I also determined that HFD-fed
Gpr120KO mice were heavier than their WT counterparts, I did not identify any
impairment in adipocyte formation or size. However, obesity studies often last for
longer than 8 weeks, and continuing to feed GPR120KO mice beyond the 8
weeks could recapitulate a significant increase in adipocyte size, as published.
Very little has been studied about the role of Gpr40 in adipogenesis as this
receptor is not highly expressed in adipose tissue128. My data establishes that
APs do indeed express low levels of Gpr40. However, knockout of Gpr40 did not
affect AP proliferation, differentiation or body weight. This finding was consistent
even when Gpr40KO APs were transplanted into WT mice, indicating that my
findings are not due to whole-body knockout of the receptor. Therefore, while
Gpr40 signaling impacts other facets of metabolism, it is less relevant for
obesity135,136.
My data has demonstrated that the FFARs Gpr120 and Gpr40 are not
required for an adipogenic response to HFD. However, these receptors play vital
roles in systemic metabolism, and Gpr120 expression is demonstrated to be
important to regulation of obesity. Further work will be needed to determine if this
function of Gpr120 is due to its WAT-specific expression or due to expression in
other tissues.

43

Chapter 4: HFD screen impacts WAT gene expression and identifies
relationships between WAT expansion mechanisms and adipose function
Results
Dietary fat screen identifies relationships between adipokine expression and
mechanisms of adipose expansion
Mechanisms of adipose tissue expansion have been linked to varying
outcomes for tissue function and systemic metabolic health, with hyperplasia
being linked to a more metabolically healthy WAT and hypertrophy being linked
to inflammation, fibrosis, and systemic insulin resistance137. I have demonstrated
that dietary fat source is highly relevant in modulating expansion primarily via
hypertrophy or hyperplasia. Furthermore, our HFDs induce varying responses in
WAT gain, enabling us to study the effects of graded levels of obesity rather than
comparing the extremes of lean or obese mice. These observations illustrate the
potential of our 45% HFD screen as a tool to study how dietary fats affect
adipose function and how these changes are related to mechanisms of adipose
expansion.
To characterize how dietary fat source impacts expression of adipokines,
qPCR was used to quantify gene expression of leptin and adiponectin in mice
which had consumed the HFD series for 12 weeks.
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Figure 10: VWAT adiponectin expression correlates negatively with hypertrophy
and dietary and plasma palmitic acid. A) VWAT expression of adiponectin from mice
fed indicated HFD for 12 weeks. Normalized to expression of β-actin. (n=5-10; one-way
ANOVA compared to SD). Correlations between average VWAT adiponectin expression
for each diet and B) average VWAT adipocyte diameter, C) average VWAT hyperplasia
quantified using the AdiCre-ER/mTmG mice, D) average VWAT AP proliferation during
the first week of HFD consumption, E) dietary palmitic acid content of each HFD, F)
average plasma concentration of nonesterified palmitic acid after 12 weeks of HFD
consumption, and G) plasma concentration of total palmitic acid after 12 weeks of HFD
consumption. (significance assessed using Spearman correlation)

In the VWAT, while the Lard, Butter, and Palm diets significantly decreased
adiponectin expression compared to SD, mice consuming the other diets
displayed no change in expression compared to SD (Figure 10A). As adiponectin
has been linked to adipocyte size47, it is perhaps expected that expression of
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adiponectin and measures of adipose tissue expansion were correlated.
Consistent with other publications47,48,50, VWAT adipocyte size was negatively
correlated to VWAT adiponectin expression, while there was no such correlation
between VWAT adiponectin expression and hyperplasia measures such as
VWAT adipocyte formation and VWAT AP proliferation (Figure 10B-D).
Interestingly, VWAT adiponectin expression was negatively correlated to palmitic
acid content in the HFD, plasma palmitic acid in the form of non-esterified fatty
acid, and total plasma palmitic acid in all forms (Figure 10E-G). These data
indicate that dietary fat type impacts VWAT adiponectin expression, possibly via
palmitic acid content of the diet.

Figure 11: SWAT adiponectin expression does not correlate to measures of
adipose expansion. A) SWAT expression of adiponectin from mice fed indicated HFD
for 12 weeks. Normalized to β-actin expression (n=5-10; one-way ANOVA). Correlations
between average SWAT adiponectin expression for each diet and B) average SWAT
adipocyte diameter for each HFD, C) average SWAT hyperplasia quantified using the
AdiCre-ER/mTmG mice, and D) average SWAT AP proliferation after HFD consumption
for one week.
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In contrast to the VWAT, SWAT expression of adiponectin was only
increased in mice that ate the Soybean diet (Figure 11A). Additionally, there were
no correlations between SWAT adiponectin expression and SWAT adipocyte
size, formation, or SWAT AP proliferation (Figure 11B-D), suggesting that there
is a depot specificity in adiponectin’s relationship to adipocyte hypertrophy and
that SWAT adiponectin expression may be regulated through other mechanisms.
In addition to adiponectin, leptin expression was also quantified after 12
weeks of diet consumption.
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Figure 12: VWAT expression of leptin is linked to hyperplasia, rather than
hypertrophy. A) VWAT expression of leptin from mice fed indicated HFD for 12 weeks.
Normalized to β-actin expression. (n=5; ** one-way ANOVA compared to SD; # unpaired
t-test to SD) Correlations between average VWAT leptin expression for each diet and B)
average VWAT adipocyte diameter after 12 weeks of diet consumption, C) average
adipocyte formation quantified in AdiCre-ER/mTmG mice, and D) average percentage of
BrdU-labeled VWAT adipocyte nuclei. Correlations between average plasma
concentration of leptin after 12 weeks of HFD consumption and E) average VWAT
adipocyte diameter, F) average VWAT adipocyte formation as quantified in AdiCreER/mTmG mice, and G) average VWAT BrdU-labeled adipocyte nuclei. F) Correlation
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between average VWAT leptin expression and average VWAT proliferative APs from
each HFD. (Significance of correlations measured using Spearman correlation) G)
VWAT leptin expression in WT or PdgfRα-Cre/Akt2fl/fl after consuming SD or HFD for 8
weeks. Normalized to expression of β-actin. (n=2-5; unpaired t-test) H) Distribution of
adipocyte diameters from WT or PdgfRα-Cre/Akt2fl/fl mice fed either SD or HFD for 8
weeks.

Mice that consumed Olive and Soybean diets had increased leptin expression
compared to SD, although expression on the Lard diet would also be considered
significant if this diet were compared directly to SD (Figure 12A). As Leptin
expression has previously been linked to adipocyte size138,139, correlations were
again performed between VWAT leptin expression and mechanisms of VWAT
expansion. In assessing correlations to determine the relationship between leptin
expression and hypertrophy and hyperplasia, VWAT leptin expression
surprisingly bore no relationship to VWAT adipocyte size (Figure 12B). Instead,
VWAT leptin expression correlated significantly with two measures of
hyperplasia—VWAT adipocyte formation quantified from the AdiCre-ER/mTmG
mouse model, and BrdU-labeled adipocyte nuclei (Figure 12C-D). To verify
whether these relationships were limited to gene expression, correlations to
quantification of plasma leptin were also analyzed. While there was no
correlation between plasma leptin and VWAT adipocyte size, plasma leptin was
significantly correlated to the proportion of BrdU-labeled adipocyte nuclei, while
adipocyte formation approached, but did not achieve, significance (Figure 12EG). These findings show that leptin production did not correlate to hypertrophy
and surprisingly correlated to measures of hyperplasia.
In examining the relationship between VWAT leptin expression and AP
activation, 9 out of the 12 HFDs demonstrated a very strong correlation to VWAT
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leptin expression (Figure 12H). However, the other three diets, HO Sunflower,
HO Safflower, and Peanut, fall away from this trend. Interestingly, these three
diets all have high rates of AP proliferation, yet lower rates of adipocyte formation
(Figure 1D), highlighting the relationship to adipocyte formation.
After observing a correlation between leptin expression and adipocyte
formation, I wanted to examine further whether adipocyte formation causes an
increase in tissue-level leptin expression or whether this relationship is merely
correlational. Akt2-/- mice lack an adipogenic response to HFD, yet have normal
rates of adipocyte formation during WAT development96, making these mice an
effective tool to study processes related to obesogenic hyperplasia. To target
Akt2 knockout to APs, I used a PdgfRα-Cre/Akt2fl/fl mouse line which targets the
APs to compare leptin expression. While HFD-fed WT mice had increased VWAT
leptin expression compared to SD, HFD failed to increase leptin expression in the
PdgfRα-Cre/Akt2fl/fl mice (Figure 12I). Furthermore, when quantifying adipocyte
size in these mice, there was no difference in adipocyte hypertrophy in HFD-fed
WT mice compared to HFD-fed PdgfRα-Cre/Akt2fl/fl mice, further demonstrating
that leptin expression is not dependent on adipocyte size (Figure 12J). This
experiment shows that increased leptin expression due to HFD consumption is
ablated in mice that are lacking an adipogenic response to the diet.
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Figure 13: SWAT leptin expression is not correlated to measures of adipose
expansion. A) SWAT expression of leptin in mice which consumed indicated HFD for 12
weeks. Data are normalized to β-actin. (n=5; one-way ANOVA) Correlations between
average SWAT leptin expression after 12 weeks of indicated HFD consumption and B)
average SWAT adipocyte diameter, C) average SWAT adipocyte formation measured in
AdiCre-ER/mTmG mice, D) average SWAT AP proliferation during first week of HFD
consumption.

In contrast to VWAT, in the SWAT, many diets—Butter, Palm, Coconut,
Soybean, and Peanut—resulted in increased leptin expression (Figure 13A).
However, SWAT expression of leptin was not correlated to any measures of
adipose expansion, including SWAT adipocyte diameter, SWAT adipocyte
formation, or the percentage of BrdU-labeled SWAT adipocyte nuclei (Figure
13B-D), showing that SWAT leptin expression is not related to any mechanisms
of adipose expansion.
Many dietary fats do not promote increased expression of inflammatory or fibrotic
markers
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Figure 14: HFD screen identifies correlation between Tnf-α and measures of
hyperplasia. VWAT expression of A) Tnf-α, B) IL-6, and C) IL-1β from mice fed
indicated HFD for 12 weeks. Gene expression is normalized to β-actin expression. (n=5,
* one-way ANOVA multiple comparisons to SD, # unpaired t-test to SD) Correlations
between average VWAT expression of Tnf-α for each diet and D) average VWAT
adipocyte diameter for each diet, E) average percentage of BrdU-labled VWAT
adipocyte nuclei, and F) average proliferation of VWAT APs after one week of HFD
consumption. (Spearman correlation)

In addition to modulation of adipokine production, obesity is linked to
measures of systemic and WAT-resident inflammation140,141 and adipose
fibrosis44,142. Increased WAT expression of inflammatory and fibrotic genes is
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linked to increased plasma insulin143 and decreased insulin sensitivity144,145. To
quantify markers of inflammation, I selected Tnf-α, IL-6, and IL-1β due to their
published increases in expression during obesity and their association to
worsened metabolic health143,145–147. Interestingly, when quantifying Tnf-α
expression in VWAT, the Fish and Palm diets resulted in increased Tnf-α
expression (Figure 14A). For comparison, a 60% Lard diet, which is classically
used in obesity studies148 was also used, which resulted in increased Tnf-α
expression when compared directly to the Chow diet. Expression of IL-6 was also
quantified, with only the 45% Lard diet resulted in increased VWAT IL-6
expression (Figure 14B). Finally, VWAT IL-1β expression was quantified with
Soybean diet resulting in increased expression (Figure 14C). Interestingly, both
45% and 60% Lard HFDs resulted in significantly lower expression of IL-1β when
compared directly to SD. These results demonstrate the importance of dietary fat
type to WAT gene expression, with some diets increasing expression of these
inflammatory genes and others having no effect.
In assessing how expression of inflammatory factors correlate to
mechanisms of adipose expansion, VWAT expression of Tnf-α was negatively
correlated to two measures of hyperplasia- proliferative APs and BrdU-labeled
adipocyte nuclei (Figure 14D-E). In contrast, there was no correlation between
Tnf-α expression and VWAT hypertrophy (Figure 14F). However, expression of
these inflammatory markers was not correlated to measures of individual fatty
acids. This correlation exemplifies the utility of this HFD series which produces a
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range of responses, allowing for correlational analyses across many
intermediates.

Figure 15: Butter HFD increases expression of some inflammatory markers in
SWAT. Mean SWAT expression of A) Tnf-α, B) IL-6, and C) IL-1β from mice which
consumed the indicated HFD for 12 weeks. Gene expression is normalized to
expression of β-actin. (n=5; one-way ANOVA multiple comparisons to SD

Gene expression of inflammatory cytokines was also characterized in
SWAT. None of the diets resulted in a significant change in change in Tnf-α
expression (Figure 15A). However, both Butter and Cocoa diets resulted in
increased expression of IL-6 in the SWAT (Figure 15B). The Butter diet also
resulted in significantly increased expression of IL-1β compared to SD (Figure
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15C). None of the SWAT expression of these inflammatory markers correlated
significantly to measures of adipose expansion (data not shown).

Figure 16: VWAT expression of fibrotic markers is primarily increased with
consumption of 60% lard diet. VWAT expression of A) Tgf-β1, B) Ctgf, C) Col1a1, and
D) Col6 in mice which had eaten one of HFDs for 12 weeks. Gene expression is
normalized to expression of β-actin. (n=5, * one-way ANOVA multiple comparisons to
SD, # unpaired t-test to SD)

In addition to inflammatory markers, Tgf-β1149, Col1a1, Col3a1, and
Col6150 were selected as fibrotic genes which are strongly upregulated with
obesity. VWAT expression of Tgf-β1 was only increased in mice consuming the
60% Lard diet. Interestingly, the 45% Lard diet resulted in the opposite change,
with a slight but significant decrease in Tgf-β (Figure 16A). VWAT expression of
Ctgf was significantly increased in mice which ate the Coconut diet (Figure 16B).
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Similar to VWAT Tgf-β1 expression, VWAT expression of Col1a1 was only
significantly increased on the 60% Lard diet when compared directly to SD
(Figure 16C). Finally, VWAT expression of Col6 was increased in the Safflower
and HO Safflower diets, although it was also increased in both the 45% and 60%
Lard diets when they were compared directly to SD (Figure 16D). These results
show that while expression of several of these genes is increased in the context
of the 60% lard HFD, the gene expression is not affected in many other diets
which also induced obesity.

Figure 17: Dietary fat source has varying effects on SWAT expression of fibrotic
markers. SWAT expression of A) Tgf-β1, B) Ctgf, C) Col1a1, and D) Col6 in mice which
consumed indicated HFD for 12 weeks. Expression is normalized to β-actin expression.
(n=5; * one-way ANOVA multiple comparisons to SD, # unpaired t-test to SD)
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Like VWAT, Tgf-β1 expression was not significantly changed in the SWAT
(Figure 17A). However, both Butter and Cocoa diets resulted in increased SWAT
expression of Ctgf compared to SD (Figure 17B). Additionally, SWAT expression
of Col1a1 was increased compared to SD on the Fish, Palm, Cocoa, and HO
Safflower diets (Figure 17C). Finally, Palm, Lard, and HO Sunflower diets
resulted in increased expression of SWAT Col6 (Figure 17D). Like the VWAT,
this data shows that gene expression is influenced by the dietary fat type and not
necessarily by the obesity status of the mouse.

Discussion
Dietary fats have been well studied for their impacts on adipose
homeostasis and effects on systemic metabolic health151. Using a screen of 12
HFDs has invoked many intermediate responses in adiposity and gene
expression, allowing for a more nuanced understanding of WAT expansion and
function. While our identified correlation between VWAT adiponectin expression
and VWAT adipocyte diameter was expected given published findings 47,48, the
depot specificity of this finding to the VWAT was particularly interesting. As
female mice lack the depot-specific adipogenic response to HFD observed in
male mice131, one could study whether adiponectin expression correlates to
hypertrophy in both depots in females as well.
The negative correlation between VWAT adiponectin expression and
palmitate is consistent with findings that palmitate inhibits adiponectin
transcription152. However, this publication focused on the study of 3T3-L1 cells in
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vitro, and therefore the in vivo data presented here represents a valuable
contribution to the field. If further work will be needed to determine if these
measures are casually linked or are merely correlational. However, a potential
hypothesis is that prolonged consumption of palmitic acid is a signal to decrease
VWAT adiponectin expression during obesity. Finally, adiponectin is also present
in oligomers of varying sizes, and the high molecular weight form of adiponectin
is negatively associated to diabetes153. Further work will be needed to determine
whether these variations in adiponectin expression also affect dynamics of
adiponectin oligomerization.
The identified correlation between VWAT leptin expression and adipocyte
formation was unexpected and novel given the expectation that leptin is highly
linked to adipocyte size138. While this correlation was surprising, it is consistent
with the published observation that plasma leptin levels do not increase until
several weeks after HFD consumption154. This time scale would be longer than is
needed to alter adipocyte hypertrophy, which can be affected with several hours
of fasting and refeeding155,156. In considering how adipose hyperplasia relates to
leptin production, two possibilities are that an increase in existing adipocytes
results in greater leptin production or that newer adipocytes produce greater
quantities of leptin. Another intriguing question would be to interrogate whether
adipocyte formation during developmental WAT establishment is a driver of the
postnatal surge in plasma leptin157. Interestingly the timing of the postnatal leptin
surge (4-12 days of age) roughly corresponds to the initial establishment of the
VWAT157,158.
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I identified that VWAT expression of Tnf-α correlated negatively with two
measures of hyperplasia—proliferating APs at the onset of diet and BrdU-labeled
adipocytes after several weeks of HFD consumption. These data are consistent
with the observations that Tnf-α treatment inhibits the differentiation of 3T3-L1
cells into mature adipocytes159 but provides in vivo findings to support these
published in vitro results. As VWAT Tnf-α expression did not correlate to my third
measure of hyperplasia, assessed using the AdiCre-ER/mTmG mouse model,
this relationship could be driven by AP proliferation and activation. This
correlation was only observed in the VWAT, rather than the SWAT, consistent
with the male VWAT being a tissue capable of an adipogenic response to HFD.
Due to the adipogenic response in female SWAT and VWAT13, studying Tnf-α
expression in female mice that consumed our HFD screen could distinguish
whether this relationship is depot specific or primarily dependent on AP
activation.
While these data show that dietary fats impact expression of Tnf-α, IL-6,
and IL-1β, no dietary fatty acids correlated with expression of these inflammatory
markers. Additionally, although many of these HFDs induced significant fat mass
gain in the mice (Figure 1: Dietary fat source determines whether VWAT expands
primarily via hypertrophy or hyperplasia. A) VWAT AP proliferation in mice fed SD or
pair-fed HFD mice for 7 days. (n=5; unpaired t-test; experiment conducted by
Christopher Church) B) AP proliferation in SWAT and VWAT normalized to the SD-fed
VWAT proliferation. Mice were fed the indicated HFD for 7 days. (n=5-2; experiment
conducted by Jennifer Kaplan) C) VWAT weights of mice which consumed the indicated
HFD for 12 weeks (n=4-5; measured by Jennifer Kaplan) D) Quantification of newly
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formed adipocytes from AdiCre-ER/mTmG mice. Mice were injected with tamoxifen then
given indicated HFD for 8 weeks. (n=3-18) E) Quantification of VWAT BrdU-labeled
adipocyte nuclei. Mice were given indicated HFD with BrdU water for one week. BrdU
water was then removed, and mice continued to consume indicated diet for a total of 12
weeks. (n=4-5). F) Mean VWAT adipocyte volume from mice which consumed the
indicated HFD for 12 weeks. (n=4-5). Correlations between VWAT mass and G) average
VWAT adipocyte diameter for each diet and H) average rate of adipocyte formation for
each diet. (Significance calculated by one-way ANOVA multiple comparisons to SD or
Spearman correlation)C, Figure 2: SWAT lacks an adipogenic response to HFDs
and expands primarily via hypertrophy. A) SWAT mass after 12 weeks of diet
consumption. (n=5; measured by Jennifer Kaplan) B) Quantification of newly formed
SWAT adipocytes in AdiCre-ER/mTmG mice after 8 weeks of HFD consumption. (n=318) C) Quantification of proportion of BrdU-labeled SWAT adipocyte nuclei in mice which
ate diet for 12 weeks. (n=4-5) D) Mean SWAT adipocyte volume after 12 weeks of
consuming indicated HFD. (n=4-5). Correlations between SWAT mass and E) SWAT
adipocyte diameter and F) SWAT adipocyte formation in AdiCre-ER/mTmG mice.
(Significance calculated by one-way ANOVA multiple comparisons to SD or Spearman
correlation)A), few significantly altered expression of these inflammatory genes.

These results were unexpected, especially as these markers were selected as
likely to be responsive to the obese state. There are varying states of obesity that
are less associated with disease, as observed by the existence of the
“metabolically healthy obese” phenotype160. While understanding of this state is
progressing, it importantly indicates that expansion of WAT does not inevitably
lead to tissue dysfunction. Additionally, while the 60% lard HFD (Research Diets,
Inc; D12492) has been extensively studied (as evidenced by thousands of
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citations), consumption of animal fats has declined over time161. My data
highlights the need to study obesity as it is induced by other fats as these
sources may result in differing phenotypes.
Finally, in characterizing expression of fibrotic markers, many of the diets
failed to induce a significant change in gene expression, with the exception of the
60% lard diet when compared directly to the Chow diet. Like the inflammatory
gene expression data, the failure of these HFDs to upregulate expression of
these fibrotic markers was unexpected given the fat mass gain while consuming
these diets, which was expected to drive fibrosis. This observation could be due
to the larger quantity of fat in this diet, and perhaps greater changes would be
observed if this HFD series contained 60% fat as well. However, these findings
also suggest that further work studying how various dietary fats impact WAT
function is needed.
For this study, the use of a series of matched HFDs was instrumental in
inducing moderate responses that could be correlated to assess how
mechanisms of WAT expansion related to expression of adipokines and markers
of inflammation and fibrosis. Future work may focus on the mechanisms of these
relationships. Unexpectedly, the expression of several inflammatory and fibrotic
genes was not changed during consumption of several of these diets. Further
work is needed to understand the connections between dietary fatty acids,
obesity, and WAT dysfunction.
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Conclusions
The development of the 3T3-L1 cell line enabled the study of signaling
and transcriptional pathways involved in adipogenesis56,162,163. Despite this a
detailed understanding of the molecular mechanisms driving adipogenesis in vivo
was lacking. Jeffery et al. provided this necessary in vivo study, establishing that
diet-induced adipogenesis is specific to the VWAT in male mice and that dietinduced adipogenesis is dependent on Akt2 signaling, in a mechanism specific to
obesity96. However, more work was needed to identify the nutritional signal which
activated this pathway.
In the work presented here, dietary oleic acid is identified as driver of AP
proliferation and differentiation. This role of oleic acid in adipogenesis is
noteworthy, given its high prevalence in the Mediterranean diet which is
associated with longevity. However, as previously discussed, the Mediterranean
diet is associated with many other lifestyle choices which are also associated
with improved health, such as high vegetable intake and frequent exercise 111.
Additionally, expansion of the adipose tissue in the face of increased dietary fat
consumption sequesters lipids away from other peripheral tissues where lipid
deposition can lead to insulin resistance119. More work is needed to study how
dietary oleic acid and its signaling impact metabolic health. This HFD series will
continue to be an exciting tool to study these relationships and the connections
between other dietary fatty acids and physiology.
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Leveraging in vitro model with primary APs, we determined that this oleic
acid signaling is dependent on Akt2 signaling and activation of lipogenesis. To
identify the mechanisms of oleic acid signaling on APs, I initially interrogated the
role of the free-fatty acid receptors Gpr120 and Gpr40. Through a variety of
experiments, I did not observe any effect of these receptors on AP activation or
adipogenesis. These results contrast with published work citing a role for ciliary
Gpr120 in the differentiation of 3T3-L1 cells164. Although further work would be
needed to characterize the discrepancies between these findings, and while this
publication utilizes in vivo models to identify the role of cilia in APs for
differentiation, the data showing the role for Gpr120 is performed entirely in the
3T3-L1 cell line. While these cells are useful for larger screens and more highthroughput experiments, validation using primary cells or an in vivo model would
have led to more robust conclusions.
Building on our observation that LXRα downregulation represents a major
change in gene expression during early HFD consumption, I used a combination
of in vitro and in vivo models to demonstrate that oleic acid reduces LXR
signaling. In addition, I identified LXRα phosphorylation as a modulator of in vivo
AP proliferation during HFD consumption. In using mice with a serine-to-alanine
point mutation in LXRα, I observed that VWAT APs demonstrated enhanced dietinduced proliferation, while SWAT APs had increased basal proliferation. Given
more time, further work to assess the role of LXRα phosphorylation on in vivo AP
differentiation would be valuable. One could determine whether these mice also
have enhanced adipocyte formation, either during the SD-fed state or during
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HFD consumption. Interestingly, a whole-body knockout of LXRα resulted in
increased SWAT leptin expression during SD consumption, consistent with the
hypotheses that LXRα plays a role in basal SWAT adipogenesis and that leptin
expression is driven by adipocyte formation.
There is also a need to study the role of LXRα in human APs. Activation of
LXRα in TH1 cells results in increased expression of aP2, a characteristic protein
of adipocytes. The aP2 promoter was also found to contain an LXRα response
element165. Little is known about the role of LXRα phosphorylation in human
pathology, beyond the observation that phosphorylated LXRα is present in
human liver166. Further work is needed to determine the role, if any, of LXRα in
human adipogenesis. However, the ability of oleic acid to increase adipogenesis
of human APs is promising for further study of this mechanism in human
samples.
In addition to mechanisms of adipogenesis, I also used this HFD series to
characterize how dietary fats affect expression of a subset of inflammatory and
fibrotic markers. While many studies have contrasted a HFD to a low-fat diet,
using a series of HFDs provides a more complex context rather than comparing
the extremes of lean and obese states. This approach is particularly useful in
comparing how mechanisms of WAT expansion are related to gene expression,
as I can analyze several intermediate responses, allowing for stronger
conclusions. This strategy led to the surprising discovery that VWAT leptin
expression is closely correlated to several measures of hyperplasia. Further work
will be needed to determine whether this increased leptin expression is due to
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more adipocytes present in the tissue or whether the newly formed adipocytes
have increased expression of leptin. Additionally, I was surprised by the temporal
disparity in the correlation between AP proliferation for a subset of the diets and
VWAT leptin expression. Given that AP proliferation is quantified after one week
of HFD consumption and leptin expression was quantified after 12 weeks, it
suggests that AP proliferation early in HFD may be predictive of eventual leptin
expression. However, this relationship is limited to diets that also induced high
rates of adipocyte formation, so further studies to understand of WAT response
to long-term consumption of the diet will be needed.
Finally, I also used this HFD series to quantify gene expression of a
subset of inflammatory and fibrotic markers. This work demonstrates the
importance of dietary fats on WAT gene expression and function. Obesity
primarily driven by hypertrophy is considered to be linked to WAT inflammation
and cell death. However, my data did not find strong correlations between
expression of these markers and hypertrophy. While these results could be
driven by the lower quantity of fat in my 45% HFD series (the classic HFD
contains 60% fat, primarily lard), they also challenge the idea that hypertrophy
and inflammation are so consistently linked. While inflammation has been well
studied using the 60% lard-based HFD167,168, these HFDs based on alternatives
fats provide a different context for the obesity. Given the diverse diet currently
consumed by humans and the declining prevalence of lard in the diet 161, these
findings highlight the need to study obesity as driven by dietary fats other than
lard.
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The role of fibrosis in obesity is disputed; it is unclear fibrosis provides a
check on ballooning adipocyte size or whether it is a marker of a pathological
tissue45,169. Like the expression of the inflammatory markers, expression of the
fibrotic markers was not significantly increased, even in diets which induced
obesity and hypertrophy. However, some of the markers were increased on the
lard HFDs, particularly the 60% lard HFD. Again, these findings highlight the
need to study obesity in a more physiologically relevant context. While many of
the HFDs induced obesity, the mechanisms of WAT expansion (whether primarily
through hypertrophy or hyperplasia) differed. Further work would be needed to
characterize how WAT gene expression and homeostasis differs on these diets
and what effects these differences play in systemic metabolic health.
This work utilized a HFD series to identify a novel mechanism that
regulates obesogenic responses and in vivo AP proliferation. This study also
allowed me to characterize the relationships between obesity and inflammation
and fibrosis. These findings further our understanding of the nutritional signals
that drive in vivo adipogenesis and the relevance of dietary fats to WAT function.
Further work is needed to define how these nutritional signals relate to measures
of metabolic health and how these concepts can be applied to human health and
disease.
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Appendix

Figure 18: Quantification of adipogenesis in female mice. BrdU pulse-chase
performed on female mice. (n=8-10; unpaired t-test) Data published in Jeffery et al.
2016103
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Methods
Animals
All experiments using animals were conducted according to guidelines by
Yale University’s Institutional Animal Care and Use Committee (IACUC). Mice
used for these studies were on the C57BL/6J background, with wild-type animals
purchased from Jackson Laboratories. Adiponectin-CreER/mTmG mice were
bred in in the Yale Animal Resource Center from Adiponectin-CreER mice gifted
by E. Rosen (Beth Israel Deaconess Medical Center, Boston, MA, USA) and
mTmG B6.129 (Cg)-Gt(ROSA)26Sortm4(ACTB-tdTomato,-EGFP)Luo/J
purchased from Jackson Laboratories. Atk2-/- mice were a kind gift from W.
Sessa (Yale University, New Haven, CT, USA). PdgfRα/Akt2flox/flox mice were
bred in the Yale Animal Resource Center from PdgfRα-Cre mice purchased from
Jackson Laboratories and Akt2flox/flox mice kindly gifted by M. Birnbaum
(University of Pennsylvania, Philadelphia, PA, USA) and mediated by K. Martin
(Yale University, New Haven, CT, USA). LXRα S196A mice were housed at New
York University, and fixed cells were kindly provided by Dr. Michael Garabedian.
Unless otherwise noted, experiments were started using male mice aged
6-8 weeks old. We use the terms VWAT to refer to the perigonadal visceral
adipose tissue and SWAT to refer to the inguinal subcutaneous adipose tissue.
Standard diet (SD) is purchased from Harlan Laboratories (2018S), and the 60%
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lard-based diet was purchased from Research Diets, Inc(D12492). The 45% kcal
HFD was purchased from Research Diets with the following catalog numbers:
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Table 1: 45% kcal high-fat diets used for screen
Fat
Lard
Olive Oil
Coconut Oil
Fish Oil
Palm Oil
Safflower Oil
Butter
Cocoa Butter
High Oleic Sunflower Oil
High Oleic Safflower Oil
Soybean Oil
Peanut Oil

Catalog #
D12451
D06022403
D05122301
D03022403
D07081501
D02062102
D06022405
D11112703
D07062503
D05122103
D05042003
D16010705

Fatty acids or tri-oleate (Sigma Aldrich, T7752) were added to the SD to
45% kcal fat. For in vivo oleic acid infusion experiments, jugular catheters were
implanted into the right vein when mice were 8 weeks old. Oleic acid (20 mM) or
vehicle (0.5% fatty acid free BSA in saline) were infused just before the dark
cycle for 5 days.
For in vivo BrdU experiments lasting one week, mice were given 0.8
mg/mL brdU in drinking water with fresh solution made every other day. For BrdU
pulse-chase experiments, BrdU was administered at 0.4 mg/mL in drinking water
for one week and then removed and normal water provided.
To treat mice with T0901317, mice were given conditioning injections
using vehicle, or medium chain triglycerides (MCT) daily for 4 days. Mice were
then given vehicle or 50 mg/kg of T0901317 daily for 3 days, along with HFD
before being sacrificed and processed for BrdU analysis.

AdiponectinCre-ER/mTmG pulse chase experiment
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This experiment was performed as previously described19. In brief, at 8
weeks of age, Adiponectin-CreER/mTmG mice were given daily injections of
tamoxifen in vegetable oil at 50 mg/kg for 5 days. The mice were then given a
week to recover and then were fed the stated diet for 8 weeks. At the end of 8
weeks, the mice were sacrificed, and their SWAT and VWAT were mounted on
slides. The tissues were imaged using confocal microscopy, and the proportion
of red to green adipocytes was quantified.

Immunohistochemistry and adipocyte size quantification
For the BrdU pulse-chase and adipocyte sizing experiments, adipose
tissue was dissected and prepared for paraffin embedding as previously
described170. In brief, tissues were dissected and fixed in zinc formalin for 24-48
hours. The tissues were then washed twice in PBS and incubated overnight in
70% ethanol. The tissues were then incubated in 75%, 95%, and 100% ethanol,
and Citrisolve (Fisher Scientific, 22143975). The tissues were incubated in
melted paraffin before finally being embedded. Paraffin blocks were sectioned by
Yale Pathology Tissue Services.
For adipocyte sizing, tissue sections were stained with Masson’s
Trichrome stain and imaged using by Yale Pathology Tissue Services. To
quantify adipocytes sizes, sections were systemically imaged and processed
using a Cell Profiler pipeline adapted from a previous publication 170. At least 300
adipocytes were quantified from each mouse. To correct for the fact that imaging
random cross sections of the roughly spherical adipoctyes was not likely to
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capture the adipocyte at its greatest diameter, a correcting program was kindly
written by Dr. Taylor Malone at Yale University. This program was adapted from
the program StripStar, which calculates a corrected distribution of spheres from a
measured distribution of sectional areas. The original StripStar program
developed for rock grain-size. The histogram of observed cell radii is compared
to a theoretical distribution where cells sizes are uniformly distributed. The
corrected histogram is calculated starting from the largest observed cell size,
iteratively "stripping off" observed cells until all cells are accounted for. A
complete desctription of the calculation can be found in Heilbronner et. al171.
For the BrdU pulse-chase experiment, sections were deparaffinized as
previously published 170. In brief, the slides were incubated in Citrisolve, 100%,
95%, 70% ethanol and PBS. Sections were surrounded with a PAP pen and
blocked with a 2% BSA in PBS solution. Sections were stained using rat antiBrdU (Abcam, 6326; 1:300) and rabbit anti-caveolin-1 (Cell Signaling 3238
1:400) and washed three times in PBS. Sections were then stained with antirabbit Rhodamine-X-Red (Jackson Immunoresearch, 111-295-144; 1:250) and
anti-rat Alexa Fluor 488 (Jackson Immunoresearch, 112-545-167; 1:250)
secondary antibodies and washed three times in PBS. DAPI Fluoromount-G
mounting media (Southern Biotech) was then used, along with a coverslip which
was sealed with nail polish. Sections were then imaged with confocal
microscopy.
To quantify phospho- LXRα in APs, sections were deparaffinized as
described. After blocking with 2% BSA in PBS, cells were incubated overnight
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with rat anti-Sca1 (BioLegend, 122501; 1:50) and rabbit anti-phospho- LXRα
(Garabedian lab, NYC; 1:50) at 4ºC. Sections were washed and incubated with
donkey anti-rat Alexa Fluor 647 (Jackson Immunoresearch, 1:800) for 2 hours at
room temperature. Seconds were then washed three times in PBS. Tyramide
SuperBoost Kit Alex Fluor 594 was used to augment the phosphor- LXRα signal
(ThermoFisher Scientific, B40944). Sections were incubated with poly-HRPconjugated secondary antibody at room temperature for 1 hour. They were then
washed three times with PBS and incubated with tyramide working solution for 5
minutes at room temperature. Sectionss were washed three times with PBS
when incubated at room temperature with DAPI (1:1000) for 15 minutes. They
were then washed three times with PBS and mounted for imaging.

Flow cytometry
Flow cytometry for analysis, isolation of APs, and BrdU quantification were
performed as previously described 19,64. In brief, adipose tissue was dissected,
minced, and digested using a 0.8 mg/mL collagenase II (Worthington
Biochemical Corporation LS004176) dissolved in a solution of 3% BSA in Hank’s
Balanced Salt Solution (HBSS; Sigma Aldrich H8264). Cells were placed in a
shaking water bath at 37ºC for one hour, shaken by hand, then continued to
shake for 15 minutes. If cells were being sorted, they were first filtered through a
100 μm filter. Cells for all experiments were filtered through a 40 μm filter. If cells
were being analyzed or sorted, they were stained using antibodies for CD45
APC-eFluor780 (eBioscience, 47-0451-80; 1:1000 for sorting, 1:500 for BrdU
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analysis), CD31 PE-Cy7 (eBioscience, 25-0311-82; 1:500), CD29 Alexa Fluor
700 (BioLegend, 102218; 1:400), CD34 Alexa Fluor 647 (Biolegend, 119314;
1:400), Sca1 Pacific Blue (BD Biosciences, 560653; 1:400), and CD24 PerCPCyanine 5.5 (eBioscience, 45-0242-80; 1:250) for 20-30 minutes on ice. Cells
were sorted with a BD FACSAriaII and analyzed using a BD LSRII analyser and
BD FACS Diva software.
If the cells were being analyzed for BrdU quantification, after digestion and
filtration, they were prestained with antibodies for CD45 APC-eFLuor780, CD31
PE-Cy7, CD29 Alexa Fluor 700 (as listed above), and Sca1 V500 (BD Horizon,
561228; 1:500) for 20-30 minutes on ice. Cells were then washed, fixed, and
permeabilized according to the instructions for Phosflow Lyse/Fix and Perm
Buffer III (BD Biosciences). Cells were then treated with Dnase (Worthington
Biochemical Corporations, LS002007) in PBS and washed with 3% BSA in
HBSS. The cells were incubated with anti-BrdU Alexa Fluor 488 or 647 (Phoenix
Flow Systems, AX647 or AX488; 1:30) overnight, washed, then stained a mixture
of antibodies for CD45, CD31, CD29 (as listed above), CD34 Alexa Fluor 647
(listed above) or Brilliant Violet 421 (BioLegend, 119321; 1:400), Sca1 Pacific
Blue or V500, and CD24 (1:200) for 30 minute at room temperature. Cells were
then washed and analyzed.
To quantify proliferation in LXRα S196A mice, Ki67 was used as a marker
of proliferation due to BrdU being a restricted substance in the New York
University mouse facility. To quantify Ki67 in APs, after antibody staining, WAT
was digested and incubated in Phosflow Lyse/Fix as discussed for the BrdU
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quantification. Cells were then washed twice in Intracellular Staining
Permeabilization Wash Buffer (BioLegend, 421002). After washing, cells were
incubated with Anti-Ki67 FITC (eBioscience, 11-5698-80; 1:50). Cells were
washed twice again in Permeabilization Wash buffer and resuspended in 3%
BSA in HBSS for analysis.

Isolation of human APs
Consent and experimental protocols to isolate human APs were reviewed
and approved by the Yale Internal Review board (HIC protocol number
1109009063). Samples were subcutaneous and abdominal adipose tissue
regarded as waste materials from bariatric surgeries or elective
abdominoplasties. Samples were stored in sterile saline solution until processing.
Tissues were washed with Krebs Ringer Phosphoate (KRP) solution
containing 0.127 M Nacl, 5 mM KCl, 2 mM sodium phosphate dibasic, and 8 mM
sodium phosphate monobasic. Tissues were minced, washed in KRP solution,
and centrifuged to separate red blood cells. Samples were then digested in KRP
solution with 3% FBS and collagenase type II for 75 minutes in a shaking water
bath at 37ºC. Samples were then filtered and washed with KRP and 3% chelexed
fetal calf serum (FCS). The floating layer of adipocytes was removed. Remaining
cells were then stained using antibodies for CD235 PE-Cy5 (BioLegend,
306605), CD45 Pacific Blue (Biolegend, 368539), GP38 PE (BioLegend,
337003), CD13 APC-Cy7 (BioLegend, 301709), CD34 APC (eBioscience), CD90
(BD Biosciences). Cells were then washed with KRP with 3% chelexed FCS.
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Cells were then selected for GP38 using EasySep Human PE positive
selection kit (Stem Cell Technologies, 17664). Cells were incubated with the PE
selection cocktail for 15 minutes, then incubated with the magnetic beads and
placed in the magnet. Cells were eluted up to 2 times using KRP with 3%
chelexed FCS. Cells were then sorted using the following marker scheme: CD45; CD235-, CD90+, GP38+, and CD34+.

Lipidomic analysis of diet, plasma and WAT
Plasma and WAT for fatty acid analysis was harvested at 6am after ad
libitum feeding. Samples were analyzed at the Mouse Metabolic Phenotyping
Center at the University of Cincinnati. Samples were saponified and methylated
for analysis of GC mass spectrometry. Retention times were compared to known
standards. Fatty acid methyl esters were separated and quantified by gas-liquid
chromatography with a Hewlett-Packard 68900 series II gas chromatograph,
using an Omegawax column (Supelco) and flame ionization detector.

Cell transplant assay
Cell transplants were performed as previously described172. In brief,
SWAT and VWAT APs were harvested and pooled from several mice as detailed
above. APs were rinsed in PBS and resuspended in PBS. Recipient mice were
anesthetized with Isothesia (Covetrus, 029405) when aged 4 weeks old. At least
0.5 million APs were injected into the tip of one recipient VWAT depot. Recipient
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mice were allowed to recover for 2 weeks and then placed on HFD for 1 week.
They were then sacrificed and analyzed for BrdU incorporation into APs.

In vitro differentiation of primary APs and 3T3-L1 cells and Oil Red O assay
Primary APs were isolated as described above. They were cultured in
growth media consisting of DMEM (ATCC, 30-2002) supplemented with 1%
penicillin/streptomycin (Sigma Aldrich, G1146) and 10% fetal bovine serum (Life
Technologies). Upon reaching confluence, media was not changed for 48 hours.
To differentiate the APs, the media was supplemented with 0.1 μg/mL insulin
(Sigma Aldrich I-5500) and maintained in this solution for 7 days with media
changings every other day. If cells were being differentiated in the presence of a
fatty acid, the fatty acid was conjugated to fatty acid free BSA (Sigma Aldrich
7030) and added to the differentiation media at 100 μM.
3T3-L1 cells were maintained in the same growth media as primary APs.
They were passaged when nearly confluent by rinsing with PBS and detaching
with 0.05% Trypsin/EDTA (Life Technologies, 25300054). When nearly confluent,
experimental cells were differentiated with an adipogenic cocktail (MDI)
consisting of 0.1 µg/mL insulin, 30 µg/mL 3-isobutyl-1methylxantine (Sigma
Aldrich, 15879), and 0.1 µg/mL dexamethasone (Sigma Aldrich, D-4902). After
48 hours, media was maintained in 0.1 µg/mL insulin and changed every other
day for 7 days.
To quantify accumulated lipid, cells were washed twice with PBS and fixed
in a solution containing 0.2% glutaraldehyde and 2% formaldehyde in PBS. The
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cells were then washed twice with PBS, twice with water, and briefly with 60%
isopropanol. After the washes, the cells were stained with a mixture of 60% Oil
Red O (Electron Microscopy Sciences 26503-02) and 40% water and then
washed briefly with 60% isopropanol and twice with water. The cells were
imaged and left in water overnight. The next day, the cells were dried for several
hour,s and then the dye was extracted using a solution of 4% NP40 in
isopropanol. The absorbance of the extraction solution was then analyzed on a
spectrophotometer at 500 nm.
Primary APs treated with inhibitors were treated 2 hours before
differentiation. Cells were treated with Glucose Transporter Inhibitor II
(Calbiochem, 10 µM) or C75 fatty acid synthase inhibitor (Sigma Aldrich; 100
µM). Cells were treated with 5 μm T0901317 in DMSO.

Transfection and luciferase reporter assay
3T3-L1 cells were cultured in a 48 well plate to nearly confluent before
transfection. Cells were transfected using Lipofectamine 2000 Transfection
Reagent (LifeTechnologies, 11668019) in OptiMEM (LifeTechnologies,
31985070). Cells were transfected with Cignal LXR Reporter Kit (Qiagen,
336841; 500 ng) for 24 hours. Media was then changed to treatment media.
LXR activity was quantified using the Luciferase Assay System (Promega,
E1500) according to the protocol. In brief, cells were lysed and spun at 12,000 g
for 2 minutes at 4ºC. Sample was then mixed with luciferase assay substrate,
and luminescence was quantified over 10 seconds.
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Isolation of RNA and real time qPCR
If analyzing gene expression in tissue, tissues were dissected, frozen in
liquid nitrogen and stored at -80˚C. The tissues were then homogenized in Trizol
LS (Life Technologies 10296010). If analyzing gene expression in cells cells,
cells were washed in PBS and then suspended in Trizol LS. If not being
processed immediately, the cells were frozen in Trizol LS at -80˚C.
RNA from both tissues and cells was harvested using a Direct-zol RNA
Miniprep kits (Zymo Research, R2051) and quantified using a nanodrop
spectrophotometer. RNA was converted to cDNA using a cDNA Reverse
Transcription kit (Applied Biosystems, 4368814). qPCR was performed with
KAPA SYBR FAST for LighCycler480 (Kapa Biosystems KK4611) on a
LightCycler 480 Real Time PCR system (Roche).

Immunoblots
For Akt2 immunoblots, primary APs were lysed using 1% IGEPAL with
protease and PhosStop phosphatase inhibitors (Roche). For LXRα immunoblots,
protein was lysed using a mixture of SDS (0.645%), sodium deoxycholate
(6.45%), Triton X100 (6.45%) supplemented with 11.5 mM sodium
pyrophosphate, 11.5 mM β-glycerophosphate disodium, and protease and
PhosStop phosphatase inhibitors. Protein was quantified using Pierce BCA
protein assay kit (Life Technologies, 23225). Protein was incubated with NuPage
2X Sample Buffer (ThermoFisher Scientific, NP0007) and Sample Reducing
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Agent (ThermoFisher Scientific, NP0009). Western blots for Akt2 were run on
10% polyacrylamide gels, while Western blots for LXRα were run on 10% BisTris gels. Protein was then transferred to PVDF membranes using the Invitrogen
NuPage system.
For Akt2 immunoblots, membranes were stained with rabbit anti-Akt2 (Cell
Signaling, 3063; 1:1000) or rabbit anti-phospho-Akt2 (Cell Signaling, 8599;
1:500) in tris-buffered saline with 0.1% Tween-20 (TBST). Membranes were then
incubated with goat anti-rabbit-HRP secondary antibody (Jackson
Immunresearch, 211-032-171; 1:10,000) and developed with SuperSignal West
Pico Chemiluminescent Substrate (Pierce).
For LXRα immunoblots, membranes were blocked with 5% BSA TBST.
They were incubated with rabbit anti-phospho- LXRα kindly provided by Dr.
Michael Garabedian’s lab at New York University (1:2000) or rabbit-anti LXRα.
They were then incubated with goat anti-rabbit-HRP (ThermoFisher Scientific,
MA5-32691; 1:500) and developed.
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